Pyoderma gangrenosum: From historical perspectives to emerging investigations

被引:22
作者
Hobbs, Misty M. [1 ]
Ortega-Loayza, Alex G. [2 ]
机构
[1] Mayo Clin, Jacksonville, FL 32224 USA
[2] Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR 97201 USA
关键词
emerging; historical; pyoderma gangrenosum; review; trends; STREAKING LEUKOCYTE FACTOR; TOPICAL TACROLIMUS; MYCOPHENOLATE-MOFETIL; ULCERATIVE-COLITIS; PYOGENIC ARTHRITIS; DAPSONE TREATMENT; PAPA SYNDROME; SKIN; EXPRESSION; THERAPY;
D O I
10.1111/iwj.13389
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Pyoderma gangrenosum (PG) is a rare disease of unknown aetiology, first described over a century ago. Initially thought to have an infectious cause, and now primarily considered an autoinflammatory condition, PG continues to be poorly understood, commonly misdiagnosed, and difficult to treat. In this review, we discuss the journey of our understanding of PG to date, including first descriptions, challenges with diagnosis, presumed pathogenesis, and treatments used. We highlight major historical landmarks and their importance, explain the rationale behind current investigations, note outstanding gaps in knowledge, and explore the future directions of PG research. We summarise what we have known, what we are working on knowing, and what we have yet to explore about PG, illustrating overall trends to invigorate future research.
引用
收藏
页码:1255 / 1265
页数:11
相关论文
共 110 条
[1]   RESOLUTION OF SEVERE PYODERMA-GANGRENOSUM IN A PATIENT WITH STREAKING LEUKOCYTE FACTOR DISEASE AFTER TREATMENT WITH TACROLIMUS (FK-506) [J].
ABUELMAGD, K ;
VANTHIEL, DH ;
JEGASOTHY, BV ;
JACOBS, JC ;
CARROLL, P ;
RODRIGUEZRILO, H ;
ACKERMAN, CD ;
FUNG, JJ ;
STARZL, TE .
ANNALS OF INTERNAL MEDICINE, 1993, 119 (07) :595-598
[2]  
AlRimawi HS, 1996, EUR J PEDIATR, V155, P759, DOI 10.1007/s004310050482
[3]  
Altman J, 1966, Minn Med, V49, P22
[4]   PYODERMA GANGRENOSUM TREATED WITH AZATHIOPRINE AND PREDNISOLONE [J].
AUGUST, PJ ;
WELLS, GC .
BRITISH JOURNAL OF DERMATOLOGY, 1974, 91 :80-82
[5]   Pyoderma gangrenosum in a patient with collagenous colitis [J].
Batra, AK ;
Levey, JM ;
Trister, J ;
Patwardhan, R .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2003, 49 (05) :S277-S279
[6]   Resolution of severe peristomal pyoderma gangrenosum with infliximab in a child with Crohn disease [J].
Batres, LA ;
Mamula, P ;
Baldassano, RN .
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2002, 34 (05) :558-560
[7]   Successful treatment of severe pyoderma gangrenosum with pimecrolimus cream 1% [J].
Bellini, V. ;
Simonetti, S. ;
Lisi, P. .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2008, 22 (01) :113-115
[8]   Successful Treatment of Autoimmune Disease-Associated Pyoderma Gangrenosum With the IL-1 Receptor Antagonist Anakinra: A Case Series of 3 Patients [J].
Beynon, Celia ;
Chin, Mei Fong ;
Hunasehally, Prasad ;
Bhagwandas, Krishnan ;
Bevan, Martin ;
Taylor, Marisa ;
Lawson, Thomas .
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2017, 23 (03) :181-183
[9]   Expression of MMP-9, MMP-10 and TNF-α and lack of epithelial MMP-1 and MMP-26 characterize pyoderma gangrenosum [J].
Bister, Ville ;
Maekitalo, Laura ;
Jeskanen, Leila ;
Saarialho-Kere, Ulpu .
JOURNAL OF CUTANEOUS PATHOLOGY, 2007, 34 (12) :889-898
[10]   Extracutaneous involvement of pyoderma gangrenosum [J].
Borda, Luis J. ;
Wong, Lulu L. ;
Marzano, Angelo V. ;
Ortega-Loayza, Alex G. .
ARCHIVES OF DERMATOLOGICAL RESEARCH, 2019, 311 (06) :425-434